Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.
Adult
Aged
Aged, 80 and over
Betacoronavirus
/ pathogenicity
Bone Marrow Cells
/ cytology
COVID-19
Cell-Derived Microparticles
/ transplantation
Cohort Studies
Coronavirus Infections
/ mortality
Critical Illness
/ mortality
Exosomes
/ transplantation
Female
Humans
Male
Mesenchymal Stem Cell Transplantation
/ adverse effects
Mesenchymal Stem Cells
/ cytology
Middle Aged
Pandemics
Pneumonia, Viral
/ mortality
SARS-CoV-2
Severity of Illness Index
Treatment Outcome
ARDS
COVID-19
MSC
SARS-CoV-2
bone marrow
exosome
Journal
Stem cells and development
ISSN: 1557-8534
Titre abrégé: Stem Cells Dev
Pays: United States
ID NLM: 101197107
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
pubmed:
10
5
2020
medline:
25
6
2020
entrez:
9
5
2020
Statut:
ppublish
Résumé
This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment. All safety endpoints were met with no adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients' clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO
Identifiants
pubmed: 32380908
doi: 10.1089/scd.2020.0080
pmc: PMC7310206
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
747-754Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL119326
Pays : United States
Organisme : NIOSH CDC HHS
ID : U01 OH011300
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
Clin Infect Dis. 2020 Mar 12;:
pubmed: 32161940
Can J Cardiol. 2020 Jun;36(6):915-930
pubmed: 32439306
Stem Cell Res. 2010 May;4(3):214-22
pubmed: 20138817
Stem Cell Res Ther. 2020 Jan 23;11(1):37
pubmed: 31973730
JAMA. 2020 Apr 22;:
pubmed: 32320003
Stem Cells. 2017 Jul;35(7):1849-1859
pubmed: 28376568
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Mol Ther. 2011 Jan;19(1):196-203
pubmed: 20842104
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Transfusion. 2019 Feb;59(S1):876-883
pubmed: 30383895
Cell Mol Immunol. 2020 Apr 7;:
pubmed: 32265513
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
J Clin Virol. 2020 Jun;127:104380
pubmed: 32353761
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Front Immunol. 2014 Dec 03;5:608
pubmed: 25520717
Neurotherapeutics. 2016 Jul;13(3):535-46
pubmed: 27324390
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
Stem Cells. 2014 Jan;32(1):116-25
pubmed: 23939814
Stem Cells Int. 2018 Jun 14;2018:3057624
pubmed: 30013600
Int J Mol Sci. 2014 Mar 07;15(3):4142-57
pubmed: 24608926
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
Int J Biol Sci. 2015 Jan 12;11(2):238-45
pubmed: 25632267
Mediators Inflamm. 2016;2016:5628404
pubmed: 27738390
Med Drug Discov. 2020 Mar;5:100019
pubmed: 32296777
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Kidney Int. 2017 Jul;92(1):114-124
pubmed: 28242034
Respir Res. 2010 Jul 09;11:94
pubmed: 20618958
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1275-1286
pubmed: 28598224